Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026

Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026
Nuvalent to present at AACR 2026

Nuvalent announced plans to present new clinical and preclinical data for its ROS1-positive non-small cell lung cancer (NSCLC) program at the AACR 2026 Annual Meeting in San Diego.

The upcoming presentation will provide updates on the development of targeted therapies for ROS1+ NSCLC, underscoring the company’s research momentum in oncology drug discovery. Further details on the specific data and clinical implications are expected to be revealed during the conference. Nuvalent’s participation highlights continued investment in next-generation treatments for difficult-to-treat cancers.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.